肠道菌群在肝胆疾病中的作用机制

韩美林; 龚振华

doi:10.3969/j.issn.1001-5256.2017.02.040

肠道菌群在肝胆疾病中的作用机制

DOI: 10.3969/j.issn.1001-5256.2017.02.040

上海交通大学附属儿童医院普外科

详细信息

中图分类号: R575
计量
- 文章访问数: 1998
- HTML全文浏览量: 20
- PDF下载量: 495
- 被引次数: 0
出版历程
- 收稿日期: 2016-09-29
- 出版日期: 2017-02-20

Mechanism of action of gut microbiota in hepatobiliary diseases

Department of General Surgery,Children' s Hospital Affiliated to Shanghai Jiao Tong University

摘要

摘要: 肠道菌群是人体最大的微生物群体,参与机体多种生理过程,肠道菌群紊乱与人类多种疾病有关。由于肝脏和胃肠道之间相互作用、相互影响,肠道菌群在肝胆疾病的发生发展过程中发挥重要作用。用宏基因组学研究能更全面更系统地了解肠道菌群特征及其对机体健康和疾病的影响。介绍了非酒精性脂肪性肝病、肝硬化、肝细胞癌及自身免疫性肝病患者肠道菌群的变化及其相关作用机制的研究进展。
- 肠杆菌科 /
- 肝疾病 /
- 胆道疾病 /
- 基因组学 /
- 综述
Abstract: As the largest microbial community in human body,gut microbiota is involved in many important physiological processes,and gut microbiota dysbiosis is associated with various diseases in humans.Due to the interaction and mutual effect between the liver and the gastrointestinal tract,gut microbiota plays an important role in the development and progression of hepatobiliary diseases.Metagenomic studies can achieve a comprehensive understanding of the features of gut microbiota and its effect on human health and diseases.This article introduces the research advances in the changes of gut microbiota among patients with nonalcoholic fatty liver disease,liver cirrhosis,hepatocellular carcinoma,and autoimmune liver diseases and related mechanisms of action.
- enterobacteriaceae /
- liver diseases /
- biliary tract diseases /
- genomics /
- review

HTML全文

参考文献(45)

[1]FIERER N,BARBERN A,LAUGHLIN DC.Seeing the forest for the genes:using metagenomics to infer the aggregated traits of microbial communities[J].Front Microbiol,2014,5(614):30-34.

[2]HANDELSMAN J,RONDON MR,BRADY SF,et al.Molecular biological access to the chemistry of unknown soil microbes:a new frontier for natural products[J].Chem Biol,1998,5(10):r245-r249.

[3]LOZUPONE CA,STOMBAUGH JI,GORDON JI,et al.Diversity,stability and resilience of the human gut microbiota[J].Nature,2012,489(7415):220-230.

[4]QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.

[5]HOLLISTER EB,RIEHLE K,LUNA RA,et al.Structure and function of the healthy pre-adolescent pediatric gut microbiome[J].Microbiome,2015,3:36.

[6]CLAESSON MJ,JEFFERY IB,CONDE S,et al.Gut microbiota composition correlates with diet and health in the elderly[J].Nature,2012,488(7410):178-184.

[7]MACFARLANE GT,MACFARLANE S.Fermentation in the human large intestine:its physiologic consequences and the potential contribution of prebiotics[J].J Clin Gastroenterol,2011,45(Suppl):s120-s127.

[8]KIM MH,KANG SG,PARK JH,et al.Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice[J].Gastroenterology,2013,145(2):396-406.

[9]BUFFIE CG,BUCCI V,STEIN RR,et al.Precision microbiome reconstitution restores bile acid mediated resistance to clostridium difficile[J].Nature,2015,517(7533):205-208.

[10]ZELANTE T,IANNITTI RG,CUNHA C,et al.Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22[J].Immunity,2013,39(2):372-385.

[11]HAMER HM,de PRETER V,WINDEY K,et al.Functional analysis of colonic bacterial metabolism:relevant to health?[J].Am JPhysiol Gastrointest Liver Physiol,2012,302(1):g1-g9.

[12]USAMI M,MIYOSHI M,YAMASHITA H.Gut microbiota and host metabolism in liver cirrhosis[J].World J Gastroenterol,2015,21(41):11597-11608.

[13]MINEMURA M,SHIMIZU Y.Gut microbiota and liver diseases[J].World J Gastroenterol,2015,21(6):1691-1702.

[14]SIOBHAN F,CLARKE,EILEEN F,et al.The gut microbiota and its relationship to diet and obesity:new insights[J].Gut Microbes,2012,3(3):186-202.

[15]YILMAZ Y,YOUNOSSI ZM.Obesity-associated nonalcoholic fatty liver disease[J].Clin Liver Dis,2014,18(1):19-31.

[16]MOUZAKI M,COMELLI EM,ARENDT BM,et al.Intestinal microbiota in patients with nonalcoholic fatty liver disease[J].Hepatology,2013,58(1):120-127.

[17]MA YY,LI L,YU CH,et al.Effects of probiotics on nonalcoholic fatty liver disease:a meta-analysis[J].World J Gastroenterol,2013,19(40):6911-6918.

[18]ZHU L,BAKER SS,GILL C,et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients:a connection between endogenous alcohol and NASH[J].Hepatology,2013,57(2):601-609.

[19]IMAJO K,FUJITA K,YONEDA M,et al.Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling[J].Cell Metab,2012,16(1):44-54.

[20]MIURA K,KODAMA Y,INOKUCHI S,et al.Toll-like receptor9 promotes steatohepatitis by induction of interleukin-1beta in mice[J].Gastroenterology,2010,139(1):323-334.

[21]QIN N,YANG F,LI A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature,2014,513(7516):59-64.

[22]KAKIYAMA G,PANDAK WM,GILLEVET PM,et al.Modulation of the fecal bile acid profile by gut microbiota in cirrhosis[J].JHepatol,2013,58(5):949-955.

[23]BAJAJ JS,RIDLON JM,HYLEMON PB,et al.Linkage of gut microbiome with cognition in hepatic encephalopathy[J].Am J Physiol Gastrointest Liver Physiol,2012,302(1):g168-g175.

[24]ZHANG HL,YU LX,YANG W,et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol,2012,57(4):803-812.

[25]SEKI E,de MINICIS S,OSTERREICHER CH,et al.TLR4 enhances TGF-beta signaling and hepatic fibrosis[J].Nat Med,2007,13(11):1324-1332.

[26]PAIK YH,SCHWABE RF,BATALLER R,et al.Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in humanhepatic stellate cells[J].Hepatology,2003,37(5):1043-1055.

[27]CHEN Y,QIN N,GUO J,et al.Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis[J].BMC Genomics,2014,15:753.

[28]DAPITO DH,MENCIN A,GWAK GY,et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell,2012,21(4):504-516.

[29]YOSHIMOTO S,LOO TM,ATARASHI K,et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature,2013,499(7456):97-101.

[30]SUNG CY,LEE NP,EL-NEZAMI H.Regulation of T Helper 17by bacteria:an approach for the treatment of hepatocellular carcinoma[J].Int J Hepatol,2012,2012:439024.

[31]LI J,SUNG CY,LEE N,et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A,2016,113(9):e1306-e1315.

[32]BINDELS LB,PORPORATO P,DEWULF EM,et al.Gut microbiota-derived propionate reduces cancer cell proliferation in the liver[J].Br J Cancer,2012,107(8):1337-1344.

[33]O'TOOLE A,ALAKKARI A,KEEGAN D,et al.Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease[J].Clin Gastroenterol Hepatol,2012,10(4):439-441.

[34]SANO H,NAKAZAWA T,ANDO T,et al.Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis[J].J Hepatobiliary Pancreat Sci,2011,18(2):154-161.

[35]LICHTMAN SN,KEKU J,CLARK RL,et al.Biliary tract disease in rats with experimental small bowel bacterial overgrowth[J].Hepatology,1991,13(4):766-772.

[36]RUDOLPH G,GOTTHARDT D,KLTERS-PLACHKY P,et al.Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis[J].J Hepatol,2009,51(1):149-155.

[37]KUMMEN M,HOLM K,ANMARKRUD JA,et al.The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls[J].Gut,2016.pii:gutjnl-2015-310500.

[38]MOLYNEAUX PL,COX MJ,WILLIS-OWEN SA,et al.The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis[J].Am J Respir Crit Care Med,2014,190(8):906-913.

[39]TORRES J,BAO X,GOEL A,et al.The features of mucosa-associated microbiota in primary sclerosing cholangitis[J].Aliment Pharmacol Ther,2016,43(7):790-801.

[40]ROSSEN NG,FUENTES S,BOONSTRA K,et al.The mucosaassociated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II[J].J Crohns Colitis,2015,9(4):342-348.

[41]ATARASHI K,TANOUE T,OSHIMA K,et al.Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota[J].Nature,2013,500(7461):232-236.

[42]SABINO J,VIEIRA-SILVA S,MACHIELS K,et al.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J].Gut,2016.pii:gutjnl-2015-311004.

[43]TABIBIAN JH,O'HARA SP,TRUSSONI CE,et al.Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model ofprimary sclerosing cholangitis[J].Hepatology,2016,63(1):185-196.

[44]TABIBIAN JH,TALWALKAR JA,LINDOR KD.Role of the microbiota and antibiotics in primary sclerosing cholangitis[J].Biomed Res Int,2013,2013:389537.

[45]BOGDANOS DP,BAUM H,GRASSO A,et al.Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis[J].J Hepatol,2004,40(1):31-39.

施引文献

资源附件(0)

访问统计